Amgen (AMGN) Tops Q3 EPS by 24c, FY Guidance Tops Views

Amgen (NASDAQ: AMGN) reported Q3 EPS of $3.69, $0.24 better than the analyst estimate of $3.45. Revenue for the quarter came in at $5.9 billion versus the consensus estimate of $5.77 billion.

GUIDANCE:

Amgen sees FY2018 EPS of $14.00-$14.25, versus the consensus of $14.02. Amgen sees FY2018 revenue of $23.2-23.5 billion, versus the consensus of $23.17 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• FTC files amicus brief challenging Amgen's Enbrel patent acquisition
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance